This HTML5 document contains 138 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n11http://dx.doi.org/10.1158/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37068863
rdf:type
wikibase:Item
schema:description
مقالة علمية نشرت في ديسمبر 2008 article scientifique articolo scientifico наукова стаття, опублікована в грудні 2008 wetenschappelijk artikel scientific article published on December 2008 videnskabelig artikel bilimsel makale artigo científico article científic vedecký článok wissenschaftlicher Artikel artículu científicu espublizáu en 2008 vetenskaplig artikel научни чланак vědecký článek
p:P577
wds:Q37068863-846F0EEE-083D-4E78-8C31-1DFD5FEADC85
wdt:P577
2008-12-01T00:00:00Z
p:P407
wds:Q37068863-D3ABCB59-1F5E-4CAB-BE56-E3D0A8CD6F68
wdt:P407
wd:Q1860
p:P2860
wds:Q37068863-B26E7528-27E7-43FE-BA6A-A415EDBBD754 wds:Q37068863-BC4EC301-0CA3-4C83-9AD4-B3C063F8C0A4 wds:Q37068863-A571B25D-FB14-4CAE-990B-29825943AE79 wds:Q37068863-AA262A38-C0B3-4A01-B7D2-E044149D1BAA wds:Q37068863-99378410-9F67-43E8-94AB-22E1CD4265F2 wds:Q37068863-A02D486C-B4F3-448D-9C52-EE36BF185747 wds:Q37068863-85136379-D8CC-4B55-BB70-B3958093DF91 wds:Q37068863-90CFC1F2-C1A2-4DCA-B4F3-765939C29873 wds:Q37068863-6C1A28F1-9F89-4AEB-A251-187E0C0339B7 wds:Q37068863-7D6816AD-9037-431C-A049-B66CE7F66440 wds:Q37068863-56E74926-0786-40EE-ABDB-FB7B10B753CB wds:Q37068863-5D802500-ACC2-402C-BDA3-63CB3C059311 wds:Q37068863-606FE415-66A0-44B4-A7AC-AD0C83C39CD9 wds:Q37068863-4B5D6741-1C08-4E15-AED4-DB8A65C1991F wds:Q37068863-4B964C3C-009E-4748-BE48-E71F57F66D71 wds:Q37068863-3AD11847-900A-4B7B-83FE-115C36D460B8 wds:Q37068863-FC87B2D2-5192-41F0-BE81-3462B741D037 wds:Q37068863-DA0AF4F1-A7E6-4B01-8854-C5238DCC61D4 wds:Q37068863-DEE070B4-CF4E-44AC-AF9F-661F0962B057 wds:Q37068863-BC812C99-0206-45B8-9137-4AC1EB4E65A2 wds:Q37068863-C7390840-E427-4C0D-9F6B-1A63815439FF wds:Q37068863-252FE0E5-940A-4160-B961-B985009BAE12 wds:Q37068863-3201F532-3F06-467C-95F4-8C30BEE7E7F4 wds:Q37068863-3800C8A7-78E4-4A43-BED7-2E8B45503CF7 wds:Q37068863-1206C254-EC12-4C3B-89EA-E8F9E8B0607E wds:Q37068863-1572D259-D4EF-4289-8B64-EC1834236CEF wds:Q37068863-2135783D-609B-43F8-A259-F9FDE0368D45 wds:Q37068863-02BD2206-605C-494E-9382-11BFC0BFABC2
wdt:P2860
wd:Q24322569 wd:Q28379145 wd:Q79961133 wd:Q79961136 wd:Q35564020 wd:Q27736012 wd:Q41127933 wd:Q63865985 wd:Q48474924 wd:Q36817132 wd:Q50882453 wd:Q24648565 wd:Q34248395 wd:Q33374574 wd:Q40129786 wd:Q27860760 wd:Q46551678 wd:Q35469572 wd:Q53640355 wd:Q35789640 wd:Q43578053 wd:Q33377626 wd:Q39388395 wd:Q36431426 wd:Q47745775 wd:Q46387525 wd:Q81414742 wd:Q36795253
p:P2093
wds:Q37068863-64F3DEDA-4322-4459-8E01-730DAE10C4FC wds:Q37068863-3C41AC23-BCE9-48CD-9C57-A51E0EE0AB45 wds:Q37068863-43ECC654-1575-4776-9DF5-764336020E09 wds:Q37068863-A8305BD6-D5C8-43DA-A021-1DC623F55112 wds:Q37068863-A178E578-B3C8-4481-92F8-A22BFD1D637D wds:Q37068863-BB2F3844-58DB-4E75-AADC-F09BE07FF4D9 wds:Q37068863-B0ADC450-286F-4B1E-943F-30CBB1B7DD64 wds:Q37068863-8701D3C1-F5B0-49DC-9659-66596A9CBCB2 wds:Q37068863-16857ACE-1077-424E-8C51-544C8EF16001 wds:Q37068863-CB51BB26-7C93-462E-9DD5-EEBEBBB903A5
wdt:P2093
David B Solit Iman Osman Jerrold Teitcher Neal Rosen Daniel Coit Susan E Krown James S Goydos David Polsky F Joseph Germino Paul B Chapman
rdfs:label
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
skos:prefLabel
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
schema:name
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
p:P50
wds:Q37068863-0C924F87-CD9A-4938-A12A-CA5D9074A4D7 wds:Q37068863-841BFE12-7EFC-4D13-91C3-973B88B1E3CE wds:Q37068863-CB420AF4-B39C-4805-856E-74C8A4DCFEFD
wdt:P50
wd:Q114408547 wd:Q88137705 wd:Q49880375
p:P1476
wds:Q37068863-03948D80-AA63-4C54-BE55-4BECB22ADF95
wdt:P1476
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma
p:P304
wds:Q37068863-64CB1F96-7941-4477-A02D-6CADBB334B7E
wdt:P304
8302-8307
p:P31
wds:Q37068863-0FC72FF0-C1A2-4562-BF54-1F7DC830C265
wdt:P31
wd:Q13442814
p:P921
wds:Q37068863-39565CD7-AA0C-46B2-B9E5-7C5C01D30C1E wds:Q37068863-445451C1-7418-4A7C-8EA7-70E4F6EBA5AB wds:Q37068863-38AC40D3-DFAD-45AA-A529-F3B4CCF1A415
wdt:P921
wd:Q18975855 wd:Q42824440 wd:Q181600
p:P698
wds:Q37068863-F56AA0DD-C480-4165-827B-286AE002411F
wdtn:P698
n9:19088048
wdt:P698
19088048
p:P1433
wds:Q37068863-D960309D-FABA-4032-B49E-001484D1E25D
wdt:P1433
wd:Q332253
p:P433
wds:Q37068863-02494092-FBA5-4DD9-880E-F485C0D9239D
p:P478
wds:Q37068863-538DEFE3-952D-4095-AA1D-27BB90BE2445
wdt:P433
24
wdt:P478
14
p:P356
wds:Q37068863-981B74A7-6B9A-4C74-A23C-BCC6C6405605
wdtn:P356
n11:1078-0432.CCR-08-1002
wdt:P356
10.1158/1078-0432.CCR-08-1002
p:P932
wds:Q37068863-92308B9F-1590-4A9E-B9E2-765B18C2BC12
wdt:P932
2629404